期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 13, 期 2, 页码 224-227出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v13.i2.224
关键词
chemotherapy; gemcitabine; pancreatic cancer; performance status; prognostic factor
Despite progress in the treatment of advanced and metastatic pancreatic cancer (PC), the outcome of this disease remains dismal for the majority of patients. Given the moderate efficacy of treatment, prognostic factors may help to guide treatment decisions. Several trials identified baseline performance status as an important prognostic factor for survival. Unfit patients with a Karnofsky performance status (KPS) below 70% only have a marginal benefit from chemotherapy with gemcitabine (Gem) and may often benefit more from optimal supportive care. Once, however, the decision is taken to apply chemotherapy, KPS may be used to select either mono- or combination chemotherapy. Patients with a good performance status (KPS = 90%-100%) may have a significant and clinically relevant survival benefit from combination chemotherapy. By contrast, patients with a poor performance status (KPS <= 80%) have no advantage from intensified therapy and should rather receive single-agent treatment. (c) 2007 The WJG Press. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据